Trying to please lenders, IMI (Inverness Medical Innovations) offers less for Ostex:
This article was originally published in Clinica
Executive Summary
Inverness Medical Innovations (IMI) has reduced its offer for osteoporosis test maker Ostex International to increase its chances of obtaining approval from its lenders. The exchange offer will now consist of a maximum of 1.9m IMI shares, compared with 2.3m originally on the table. IMI, a provider of women's health and nutritional products of Waltham, Massachusetts, and Ostex, of Seattle, Washington, hope to complete the transaction in the second quarter of 2003.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.